Douglas Johnson, MD, MSCI received his MD from the University of Alabama School of Medicine and completed internal medicine residency at Duke University before coming to Vanderbilt for hematology/oncology fellowship. He has been on faculty at Vanderbilt since 2014, is an Associate Professor of Medicine, is now the director of the melanoma, Vanderbilt Precision Oncology, Vanderbilt Program for Optimizing Immunotherapy (V-POINT) programs. He holds the Susan and Luke Simons Endowed Directorship.

Dr. Johnson’s research focuses on optimizing and extending the use of novel immune and targeted therapies in melanoma and other cancers, to identify biomarkers of response and resistance, to understand and more effectively manage the side effects of these new therapies, and to develop new treatment options. He is the local and national principal investigator for numerous clinical trials and his research is funded by individual philanthropy, National Cancer Institute, the American Society of Clinical Oncology, the National Comprehensive Cancer Network, and the Melanoma Research Foundation.